Publicacións en colaboración con investigadores/as de Hospital Universitario de Guadalajara (21)

2024

  1. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789

2023

  1. Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib

    Clinical Genitourinary Cancer, Vol. 21, Núm. 3, pp. e166-e174

  2. Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study

    PLoS ONE, Vol. 18, Núm. 5 May

2022

  1. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

    European Journal of Cancer, Vol. 175, pp. 110-119

2021

  1. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

    BMC Cancer, Vol. 21, Núm. 1

2020

  1. Latest progress in molecular biology and treatment in genitourinary tumours

    Clinical and Translational Oncology, Vol. 22, Núm. 12, pp. 2175-2195

2019

  1. BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

    Journal of Patient-Reported Outcomes, Vol. 3, Núm. 1

2017

  1. Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy

    Clinical and Translational Oncology, Vol. 19, Núm. 10, pp. 1175-1182

2016

  1. Role of taxanes in advanced prostate cancer

    Clinical and Translational Oncology, Vol. 18, Núm. 10, pp. 972-980

2015

  1. Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer

    Critical Reviews in Oncology/Hematology, Vol. 96, Núm. 2, pp. 308-318

2012

  1. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer

    Critical Reviews in Oncology/Hematology, Vol. 83, Núm. 3, pp. 341-352

2011

  1. Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients

    Expert Opinion on Pharmacotherapy, Vol. 12, Núm. 16, pp. 2433-2439

2010

  1. Colorectal cancer prognosis twenty years later

    World Journal of Gastroenterology, Vol. 16, Núm. 7, pp. 862-867

2009

  1. Prostate stem cells and cell differentiation

    Handbook of Prostate Cancer Cell Research: Growth, Signalling, and Survival (Nova Science Publishers, Inc.), pp. 211-241

  2. Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients

    Clinical and Translational Oncology, Vol. 11, Núm. 11, pp. 727-736

  3. The role of COX-2 in prostate carcinoma: Therapeutical implications

    Handbook of Prostate Cancer Cell Research: Growth, Signalling, and Survival (Nova Science Publishers, Inc.), pp. 363-388

2008

  1. Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients

    Journal of Medical Genetics, Vol. 45, Núm. 9, pp. 557-563

2007

  1. Cyclooxygenase-2 (COX-2): A molecular target in prostate cancer

    Clinical and Translational Oncology, Vol. 9, Núm. 11, pp. 694-702

  2. Prostate cancer and Hedgehog signalling pathway

    Clinical and Translational Oncology, Vol. 9, Núm. 7, pp. 420-428

  3. Prostate carcinoma and stem cells

    Clinical and Translational Oncology, Vol. 9, Núm. 2, pp. 66-76